Idarubicin Pharmacokinetics

  • E. Schleyer
  • S. Budeus
  • J. Reinhardt
  • C. Rolff
  • T. Büchner
  • W. Hiddemann
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

Idarubicin is one of the most recently introduced agents which has gained increasing interest andd is beginning to be widely administered both for the first and second line treatment of AML as well as in breast cancer [1, 2]. In order to provide the basis for its clinical use the pharmacokinetics of this agent have been the topic of many investigations [3–5]. This paper gives an overview of the available literature on the pharmacokinetics of idarubicin and its main metabolite idarubicinol after intravenous and oral administration and demonstrates the results from our own pharmacokinetic studies on the pharmacokinetics of idarubicin after repeated oral administration. In order to obtain an overwiew of the pharmacokinetics of idarubicin the following key determinants must be evaluated.

Keywords

Toxicity HPLC Leukemia Cytosine Methoxy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Robert J, Rigal-Huguet F, Harousseau JL, Pris J, Huet S, Reiffers J, Hurtelopu P, Tamassia V (1987) Pharmacokinetics of Idarubicin after daily intravenous administration in leukemic patients. Leuk Res 11: 961–964PubMedCrossRefGoogle Scholar
  2. 2.
    Elbaek K, Ebbehoej E, Jakobsen A, Juul P, Rasmusen S, Bastholt L, Dalmark M. Steiness E (1989) Pharmacokinetics of oral Idarubicin in breast cancer patients with reference to antitumor activity and side effects. Clin Pharmacol Ther 5: 627–634CrossRefGoogle Scholar
  3. 3.
    Broggini M, Sommacampagna B, Paolini A, Ersilia D, Grazia D (1986) Comparative metabolism of daunorubicin and 4-demethosydaunorubicin in mice and rabbits. Cancer Treat Rep 6: 697–702Google Scholar
  4. 4.
    Zhini G,Vicario GP, Lazzati M, Armacone F (1986) Disposition and metabolism of (14-C) 4-demethoxydaunorubicin HCL (Idarubicin) and (14-C) daunorubicin HCL in the rat. Cancer Chemother Pharmacol 16: 107–115Google Scholar
  5. 5.
    Tamassia V, Pacciarini MA, Moro E, Piazza E,Vago G, Libretti A (1987) Pharmacokinetic study of intravenous and oral Idarubicin in cancer patients. Int J Clin Pharmacol Res 5: 419–426Google Scholar
  6. 6.
    Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G (1977) Modellentwicklung in der Pharmakokinetik. Drug Res 27: 904–911Google Scholar
  7. 7.
    Smith DB, Margison JM, Lucas SB, Wilkinson PM, Howel A (1987) Clinical pharmacology of oral and intravenous 4-demethosydaunorubicin. Cancer Chemother Pharmacol 19: 138–142PubMedCrossRefGoogle Scholar
  8. 8.
    Speth P, van de Loo F, Linssen P, Wessels H, Haanen C (1986) Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunorubicin. Clin Pharmacol Ther 12: 643–649CrossRefGoogle Scholar
  9. 9.
    Pannuti F. Camaggi CM, Strocchi E, Comparsi R, Angelelli B, Pacciarini MA (1986) Low dose oral administration of 4-demethoxydaunorubicin ( Idarubicin) in advanced cancer patients. Cancer Chemother Pharmacol 16: 295–299PubMedCrossRefGoogle Scholar
  10. 10.
    Lu K, Savaraj N, Kavanagh L, Feun LG, Burgess M, Bodey GP, Loo TL (1986) Cancer Chemother Pharmacol 17: 143–148PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • E. Schleyer
    • 1
  • S. Budeus
    • 1
  • J. Reinhardt
    • 1
  • C. Rolff
    • 1
  • T. Büchner
    • 1
  • W. Hiddemann
    • 1
  1. 1.Department of Internal MedicineUniversity of MünsterMünsterGermany

Personalised recommendations